Acrivon Therapeutics - ACRV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $22.88
  • Forecasted Upside: 187.74%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$7.95
▼ -0.16 (-1.97%)

This chart shows the closing price for ACRV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acrivon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACRV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACRV

Analyst Price Target is $22.88
▲ +187.74% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Acrivon Therapeutics in the last 3 months. The average price target is $22.88, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 187.74% upside from the last price of $7.95.

This chart shows the closing price for ACRV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Acrivon Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$25.00 ➝ $25.00Low
5/14/2024HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $22.00Low
4/29/2024LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
4/26/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$18.00 ➝ $25.00Low
4/25/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$14.00 ➝ $17.00Low
4/25/2024Piper SandlerBoost TargetOverweight ➝ Overweight$26.00 ➝ $30.00Low
4/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
4/5/2024LADENBURG THALM/SH SHLower TargetBuy ➝ Buy$18.00 ➝ $14.00Low
4/1/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$18.00Low
4/1/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$14.00Low
3/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
3/1/2024JMP SecuritiesInitiated CoverageMkt Outperform$14.00Low
11/10/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$25.00 ➝ $24.00Low
10/5/2023Maxim GroupInitiated CoverageBuy$24.00Low
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
8/18/2023JonestradingInitiated CoverageBuy$26.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $20.00Low
6/1/2023OppenheimerInitiated CoverageOutperform$25.00Low
5/8/2023BMO Capital MarketsInitiated CoverageOutperform$25.00Low
4/27/2023LADENBURG THALM/SH SHInitiated CoverageBuy$22.00Low
4/20/2023HC WainwrightInitiated CoverageBuy$24.00Low
12/12/2022Jefferies Financial GroupInitiated CoverageBuy$17.00Low
12/12/2022CowenInitiated CoverageOutperformLow
12/12/2022CowenInitiated CoverageOutperformLow
12/11/2022Piper SandlerInitiated CoverageOverweight$25.00Low
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 11 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/25/2024
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Acrivon Therapeutics logo
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Read More

Today's Range

Now: $7.95
Low: $7.93
High: $8.26

50 Day Range

MA: $8.19
Low: $5.47
High: $10.54

52 Week Range

Now: $7.95
Low: $3.19
High: $14.03

Volume

52,182 shs

Average Volume

137,924 shs

Market Capitalization

$245.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Acrivon Therapeutics?

The following Wall Street analysts have issued research reports on Acrivon Therapeutics in the last twelve months: BMO Capital Markets, HC Wainwright, JMP Securities, Jonestrading, LADENBURG THALM/SH SH, Maxim Group, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for ACRV.

What is the current price target for Acrivon Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Acrivon Therapeutics in the last year. Their average twelve-month price target is $22.88, suggesting a possible upside of 187.7%. Piper Sandler has the highest price target set, predicting ACRV will reach $30.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $14.00 for Acrivon Therapeutics in the next year.
View the latest price targets for ACRV.

What is the current consensus analyst rating for Acrivon Therapeutics?

Acrivon Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACRV.

What other companies compete with Acrivon Therapeutics?

How do I contact Acrivon Therapeutics' investor relations team?

The company's listed phone number is 617-207-8979 and its investor relations email address is [email protected]. The official website for Acrivon Therapeutics is www.acrivon.com. Learn More about contacing Acrivon Therapeutics investor relations.